AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33295007
Drug: Apalutamide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide + androgen deprivation therapy
Trial: 33295007
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + androgen deprivation therapy
Trial: 32825070
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of smart gamification and financial rewards
Trial: 33061332
Drug: Intensified postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified postoperative physical therapy treatment including daily supervised early mobilization and coached deep breathing exercises with positive expiratory pressure (PEP)
Trial: 34997449
Drug: FTD/TPI 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTD/TPI 35 mg/m2
Trial: 33762689
Drug: Bifidobacterium longum
RxNorm normalized name: Bifidobacterium longum
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium longum subsp. infantis (B. infantis) EVC001 (EVC) daily for 21 days
Trial: 35321558
Drug: Non-RAS inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-RAS inhibitors (calcium channel blockers and diuretics)
Trial: 35321558
Drug: RAS inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAS inhibitors (ACE inhibitors, ARBs, and β-blockers)
Trial: 35321558
Drug: Baseline RAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline RAS inhibitor or non-inhibitor treatments
Trial: 32968290
Drug: Self-medication practices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-medication practices
Trial: 34907064
Drug: Physiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy and cognitive behavioural therapy (CBT) for 9 weeks each
Trial: 34657055
Drug: Regorafenib (Rego)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib (Rego) 160 mg/kg body weight orally every 28 days for 21 days
Trial: 34657055
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus Bevacizumab (SB), S-1 orally every 42 days for 28 days and Bev 5 mg/kg intravenously on days 1, 15, and 29
Trial: 33369354
Drug: Focused ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused ultrasound subthalamotomy (active treatment)
Trial: 34924287
Drug: GnRHa supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa supplementation (two boluses of triptorelin 0.1 mg)
Trial: 32598098
Drug: 40% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% hydrogen peroxide (bleaching agent)
Trial: 32598098
Drug: 35% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% carbamide peroxide (bleaching agent)
Trial: 35315627
Drug: Perioperative cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative cognitive therapy combined with rehabilitation exercise
Trial: 33793078
Drug: Oat consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat consumption (80 g oats containing 3 g beta-glucan daily for 45 days)
Trial: 34815362
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the retesting rate within 4 months of treatment
Trial: 34815362
Drug: Increasing partner
RxNorm normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing partner treatment rate from 30% to 50%
Trial: 36180944
Drug: Best established
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best established treatment only (BET)
Trial: 33761679
Drug: Tanreqing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanreqing injection combined with azithromycin
Trial: 33415857
Drug: Neurology treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurology treatment
Trial: 35617104
Drug: Treosulfan (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treosulfan (30 g/m2 IV)
Trial: 35617104
Drug: Busulfan (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulfan (6.4 mg/kg IV)
Trial: 34145306
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mitotoxic antibiotic without supplementation)
Trial: 32195962
Drug: Tablet computer-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet computer-based cognitive training program (30 minutes per session, twice a week for 12 weeks)
Trial: 32195962
Drug: Tablet computer-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet computer-based cognitive training program
Trial: 33909260
Drug: Shuanghuanglian (SHL)
RxNorm normalized name: TRACH CANNULA,SZ 10 SHLY #10IC10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuanghuanglian (SHL) treatment (14-day treatment)
Trial: 33909260
Drug: High-dose Shuanghuanglian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Shuanghuanglian (SHL) treatment
Trial: 35524205
Drug: Camrelizumab plus
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab plus chemotherapy (IO-CT)
Trial: 32780660
Drug: Brigatinib 180
RxNorm normalized name: brigatinib 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 180 mg once daily (7-day lead-in at 90 mg once daily)
Trial: 33766695
Drug: Structured hypertension
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured hypertension education program (once weekly education session for 4 weeks, home blood pressure monitoring, dose changes in antihypertensives)
Trial: 35113805
Drug: AZD4017 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4017 (400 mg oral, bi-daily for 35 days)
Trial: 33152538
Drug: Concurrent systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent systemic antibiotics at catheter insertion
Trial: 33152538
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics at catheter insertion
Trial: 36105248
Drug: Antithrombotic elastic
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic elastic socks combined with pneumatic treatment intervention
Trial: 32300579
Drug: Intravenous ACBMNC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ACBMNC infusion (5 × 10^7 cells/kg)
Trial: 37343576
Drug: Balanced crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced crystalloid solution (Plasma-Lyte 148)
Trial: 34077911
Drug: Informational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Informational intervention (monthly newsletters about park-based PA opportunities, park program brochures, trail maps, and activity guides)
Trial: 36530477
Drug: Trigeminal ganglion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigeminal ganglion block (2% lidocaine 0.5 mL)
Trial: 35499362
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Epilobium fleischeri extract (twice daily for 4 weeks)
Trial: 32758405
Drug: Endorsement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endorsement of treatment methods
Trial: 33957621
Drug: Triamterene 50
RxNorm normalized name: triamterene 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene 50 mg twice daily
Trial: 35187621
Drug: High-dose ghrelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ghrelin (0.5 µg/kg/h)
Trial: 35187621
Drug: Low-dose ghrelin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ghrelin (0.25 µg/kg/h)
Trial: 35187621
Drug: Ghrelin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin (both doses)
Trial: 36478501
Drug: Tramadol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (100 mg/day, escalated to a maximum of 400 mg/day)
Trial: 37084125
Drug: Tight glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glycemic control (80–110 mg/dL)
Trial: 37084125
Drug: Moderate glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate glycemic control (110–140 mg/dL)
Trial: 35960115
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ultrasonic debridement and cortex phellodendri compound fluid (CPCF)
Trial: 35960115
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ultrasonic debridement and CPCF
Trial: 33827990
Drug: AD-203 (rebamipide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD-203 (rebamipide 150 mg) twice daily for 2 weeks
Trial: 33827990
Drug: Mucosta (rebamipide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosta (rebamipide 100 mg) thrice daily for 2 weeks
Trial: 33827990
Drug: AD-203 (rebamipide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD-203 (rebamipide 150 mg)
Trial: 33827990
Drug: Mucosta (rebamipide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosta (rebamipide 100 mg)
Trial: 32651644
Drug: Acetaminophen (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1000 mg) + Codeine (30 mg)
Trial: 32651644
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Acetaminophen and Acetaminophen + Codeine)
Trial: 32186286
Drug: Regular Platform
RxNorm normalized name: Autolet Regular Platform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular Platform (RP) implants
Trial: 32186286
Drug: Platform Switching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform Switching (PS) implants
Trial: 32658610
Drug: udenafil treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: udenafil treatment
Trial: 33179377
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin 2.5 mg/kg
Trial: 33179377
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin 3.4 mg/kg
Trial: 37061109
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 12 months
Trial: 35886341
Drug: Iontophoresis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresis with Perskindol gel from the positive pole ("+" iontophoresis)
Trial: 35886341
Drug: Iontophoresis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iontophoresis with Perskindol gel from the negative pole ("-" iontophoresis)
Trial: 35886341
Drug: Anodic galvanic
RxNorm normalized name: OCTINOXATE 0.068 g in 1 g TOPICAL LIPSTICK [ESIKA PRO HD COLOR HIGH DEFINITION COLOR SPF 20 (HD BERRY BALCANIC) - RED]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodic galvanic treatment
Trial: 32443285
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment and prolonged antimicrobial therapy (median duration of antibiotics was 12 weeks)
Trial: 33028550
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (single‐pulse TMS to primary motor cortex (M1) above resting motor threshold)
Trial: 33028550
Drug: Inactive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive treatment (single‐pulse TMS to M1 below resting motor threshold)
Trial: 32761909
Drug: Topical phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical phenytoin (10% phenytoin USP)
Trial: 36224325
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg twice a day) in group A (S+)
Trial: 36224325
Drug: Trimetazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (20 mg twice a day) in group C (S-)
Trial: 36344924
Drug: Cisatracurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.15 mg/kg
Trial: 35648286
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of immunoglobulin
Trial: 35648286
Drug: Eculizumab (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (monoclonal antibody against C5)
Trial: 35648286
Drug: ANX005 (humanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANX005 (humanized recombinant antibody against C1q)
Trial: 32649617
Drug: Prophylactic implantation
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic implantation of a biological intraperitoneal mesh using Strattice (mesh group)
Trial: 34045378
Drug: Start antiplatelet
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start antiplatelet therapy
Trial: 32996352
Drug: Schema-enhanced parent
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schema-enhanced parent behavior therapy (SPBT)
Trial: 34928302
Drug: mRNA vaccine
RxNorm normalized name: RSV mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA vaccine (BNT162b2 or mRNA‐1273)
Trial: 34928302
Drug: Vector vaccine
RxNorm normalized name: COVID-19 non-replicating viral vector vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vector vaccine (Ad26COVS1)
Trial: 34928302
Drug: Both mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both mRNA and vector vaccines
Trial: 34465677
Drug: Neurodynamics Nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodynamics Nerve Flossing Technique (NFT) combined with conventional therapy program
Trial: 34465677
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy program
Trial: 33210773
Drug: Multifactorial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifactorial intervention by primary care nurses including motivational interview and individualized prescription of physical activity (150 min/week)
Trial: 35343881
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g Egg Protein Hydrolysate (EPH)
Trial: 35343881
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g Egg Protein Hydrolysate (EPH)
Trial: 35343881
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g and 1 g Egg Protein Hydrolysate (EPH)
Trial: 33184931
Drug: Atrasentan 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 0.75 mg for 6 weeks
Trial: 36476310
Drug: ACME (Antrodia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACME (Antrodia Cinnamomea mycelia extract) 250 mg daily for 12 weeks
Trial: 34126249
Drug: Ranibizumab or
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab or Bevacizumab treatment for neovascular AMD
Trial: 32323609
Drug: KP-100 (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KP-100 (recombinant human hepatocyte growth factor) administered intrathecally
Trial: 34480579
Drug: Zolpidem 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 30 mg
Trial: 33332919
Drug: Phrenic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phrenic nerve block (PNB) with 10 mL of 0.375% ropivacaine
Trial: 39689189
Drug: Half-dose tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose tenecteplase
Trial: 33310801
Drug: Fixed-dose antihypertensive
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose antihypertensive monotherapy
Trial: 33310801
Drug: Low-dose monotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose monotherapy (defined daily dose: 0.5 units)
Trial: 34134574
Drug: Hyperthermia combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermia combined with TPF induction chemotherapy (5-fluorouracil, cisplatin, and docetaxel)
Trial: 34134574
Drug: TPF induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF induction chemotherapy alone
Trial: 34134574
Drug: Hyperthermia combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermia combined with TPF induction chemotherapy
Trial: 35538465
Drug: Self-administered CRAFT
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered CRAFT (control group)
Trial: 34971475
Drug: Carboxytherapy at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxytherapy at a flow rate of 30 ml/min
Trial: 34971475
Drug: Carboxytherapy at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxytherapy at a flow rate of 60 ml/min
Trial: 34360315
Drug: ProLiSMental psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProLiSMental psychoeducational intervention (4 or 8 weekly sessions of 90 or 45 min)
Trial: 33041022
Drug: HYD diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYD diet (75 mg/kg Zn from HYD)
Trial: 33041022
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (75 mg/kg Zn from zinc sulfate)
Trial: 33041022
Drug: FR treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FR treatments (40% of ad libitum feed intake)
Trial: 33041022
Drug: AL treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL treatments (ad libitum fed)
Trial: 35332591
Drug: Intralymphatic immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralymphatic immunotherapy with birch and 5-grass allergen extracts (10,000 SQ units/ml, ALK-Abelló)
Trial: 35332591
Drug: Intralymphatic immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralymphatic immunotherapy with birch and placebo
Trial: 35332591
Drug: Intralymphatic immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralymphatic immunotherapy with 5-grass and placebo
Trial: 33723066
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel administration
Trial: 33723066
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel administration
Trial: 32171667
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) - 90 min exposure to 100% O2 at 2 atmospheres absolute, daily for 5 days a week for 4 weeks before surgery and 10 additional sessions after first-stage surgery
Trial: 35948268
Drug: n‐3 long‐chain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 long‐chain polyunsaturated fatty acid supplementation (4.2 g per day)
Trial: 34480530
Drug: Preoperative systemic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative systemic chemotherapy
Trial: 33351042
Drug: Digoxin (n=80;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (n=80; mean dose 161 μg/d)
Trial: 33351042
Drug: Bisoprolol (n=80;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (n=80; mean dose 3.2 mg/d)
Trial: 33378384
Drug: High-dose budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose budesonide
Trial: 32419128
Drug: Manual chest
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual chest compression (CC)
Trial: 32694183
Drug: Long-term oxygen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oxygen therapy (nasal cannula)
Trial: 35607776
Drug: NeuroEPO (nasally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuroEPO (nasally administered recombinant EPO)